A Phase 1/2a Multicenter Open-Label First in Human Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of DB-1305 in Subjects with Advanced/Metastatic Solid Tumors
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Ovarian And Endometrial CancersAdvanced/metastatic Solid Tumors
-
Age: Between 18 Year(s) - 100 Year(s)
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Histologically or cytologically confirmed unresectable advanced/ metastatic solid tumors who have relapsed or progressed on or after standard systemic treatments or for which no standard treatment is available
- Has a life expectancy of greater than 3 months
- Is willing to provide pre-existing resected tumor samples or undergo fresh tumor biopsy for the measurement of trophoblast cell surface antigen 2 (Trop-2) level and other biomarkers if no contraindication
You may not be eligible for this study if the following are true:
-
- Uncontrolled or significant cardiovascular disease
- Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening
- Clinically uncontrolled pleural effusion or ascites that requires pleurocentesis or abdominal tapping for drainage within 2 weeks prior to randomization
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.